The primary granule protein (PGP), human neutrophil elastase (HNE), is often associated with inflammatory-type reactions but also has a role in granulopoiesis. 1 PGP proteases, including HNE, normally provide negative feedback of granulopoiesis by controlling the availability of granulocyte colony-stimulating factor (G-CSF) proportionate to the relative abundance of mature granulocytes that are greatly elevated in number as a clinical feature of chronic myeloid leukaemia (CML).
HNE added to normal CD34 þ stem cells in culture blocks granulocyte macrophage (GM) colony formation and induces apoptosis.
1,2 The G-CSF receptor is not digested; instead HNE targets G-CSF protein exerting a negative feedback on cytokine activity. 1 High plasma levels of HNE 2 and low G-CSF 3 have been reported in CML. Moreover, it is known that Ph þ cells can invoke autocrine G-CSF cytokine production. 4 Taken together, these data suggest that HNE may contribute to the CML phenotype of Ph þ clonal dominance as Ph À normal cells die without growth factors.
Indeed, it has been shown that CML CD34 þ cells are insensitive to exogenously added HNE, whereas normal CD34 þ that are not cytokine-independent undergo apoptosis when cultured in vitro in serum-free medium supplemented with stem cell factor, G-and GM-CSF to which HNE is added. 2 Elafin is a naturally occurring inhibitor of HNE, and can restore normal proliferation when added to mixed CML/normal cell cultures (El-Ouriaghli et al. Blood 2003; 102: 230a; abstract). We sought to determine whether HNE levels are elevated in CML bone marrow (BM) and peripheral blood (PB) samples taken pre-and post-treatment with the tyrosine kinase inhibitor, imatinib mesylate (IM) and to determine any correlation with disease stage. Consequently, it may be possible to target HNE with an inhibitor modelled on the naturally occurring anti-protease, elafin or elastase-specific inhibitor. 5 PB or BM samples were collected into ethylenediaminetetraacetic acid tubes from CML and non-CML patients; PB was also drawn from healthy volunteers, all with informed consent. Non-CML and healthy individuals had white blood cell counts (WBC) in the normal range (o10 Â 10 9 /l). Samples from CML patients were collected at various time intervals before and during the course of their treatment with IM. The plasma supernatant from all samples was separated from cellular components by centrifugation and stored frozen (À201C) until required. A total of 105 samples were analysed (Table 1) . HNE protein was measured using a highly sensitive, specific enzyme-linked immunosorbent assay (ELISA) kit (BioVendor, The Netherlands) for the quantitative measurement of the complex of HNE with alpha-1 proteinase inhibitor in plasma. Serum was not suitable as during clotting, HNE can be released in vitro.
Measurement of plasma HNE by ELISA showed that at diagnosis (chronic phase (CP) CML, n ¼ 16), PB HNE was significantly elevated (1934795 ng/ml, mean7s.e.m.) with respect to normal controls (6473 ng/ml, n ¼ 9; P ¼ 0.002) ( Figure 1 ). HNE was also significantly elevated in CML BM supernatant separated from samples taken before IM treatment (52517162 ng/ml, n ¼ 6) with respect to non-CML controls (21547695 ng/ml, n ¼ 3; P ¼ 0.003). After treatment with IM for longer than 4 weeks, PB HNE levels normalized (5173 ng/ml, n ¼ 13) in parallel with correction of WBC ( Table 2) . At 12 weeks post-IM, there were no significant differences in HNE levels between those patients in complete cytogenetic remission (CCR) versus cytogenetic non-responders in their PB (61713, n ¼ 4 versus 58710 ng/ml, n ¼ 5) or BM (26497282 versus 18817471 ng/ml; both groups n ¼ 6 with normal WBC), with all CML BM samples not significantly different from non-CML controls.
In CP CML at diagnosis, PB HNE levels were significantly elevated relative to normal controls. Interestingly, we have previously noted an inverse correlation between total WBC and G-CSF protein levels in CML patients in early CP 3 that, based on the current observation, may result in part from degradation of G-CSF by HNE. Yong et al. 6 have shown a correlation between longer survival times and high elastase (ELA2) or proteinase-3 (PR3) gene expression with low CD7 in CML. However, treatment of our cohort of patients with IM resulted in normalization of PB HNE protein and WBC. Further, at 12 weeks post-IM, there were no differences in either PB or BM HNE protein levels between CML patients in CCR and cytogenetic non-responders, or between CML BM samples and non-CML controls. In conclusion, HNE protein is an unsuitable differential target for therapy in IM-treated CP CML. Po0.005, NS (not significant) with respect to pre-IM treatment. NS (not significant) with respect to normal controls (PB: 6473 ng/ml, non-CML marrow: 21547695 ng/ml).
